October 31, 2016 10:16 AM EDT
Bioregnum
Pharma
Opinion

2016's drug pric­ing head­winds threat­en a hur­ri­cane of new reg­u­la­tions

Those head­winds aimed at rou­tine drug price in­creas­es in the US is now be­com­ing a gale force po­lit­i­cal storm that is draw­ing down share prices …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Biose­cure bill is left out of end-of-year de­fense pack­age, deal­ing blow to chances

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

Dutch biotech nabs €85M to po­si­tion in­flam­ma­to­ry an­ti­body for a phar­ma buy­er

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times